These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37890391)

  • 1. Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the HEALing Communities Study.
    Davis A; Stringer KL; Drainoni ML; Oser CB; Knudsen HK; Aldrich A; Surratt HL; Walker DM; Gilbert L; Downey DL; Gardner SD; Tan S; Lines LM; Vandergrift N; Mack N; Holloway J; Lunze K; McAlearney AS; Huerta TR; Goddard-Eckrich DA; El-Bassel N
    Int J Drug Policy; 2023 Dec; 122():104241. PubMed ID: 37890391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Communities that Heal (CTH) intervention on perceived opioid-related community stigma in the HEALing Communities Study: results of a multi-site, community-level, cluster-randomized trial.
    Davis A; Knudsen HK; Walker DM; Chassler D; Lunze K; Westgate PM; Oga E; Rodriguez S; Tan S; Holloway J; Walsh SL; Oser CB; Lefebvre RC; Fanucchi LC; Glasgow L; McAlearney AS; Surratt HL; Konstan MW; Huang TT; LeBaron P; Nakayima J; Stein MD; Rudorf M; Nouvong M; Kinnard EN; El-Bassel N; Tilley J; Macoubray A; Savitzky C; Farmer A; Beers D; Salsberry P; Huerta TR
    Lancet Reg Health Am; 2024 Apr; 32():100710. PubMed ID: 38510790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in perceptions of community stigma towards opioid use disorder between community substance use coalition members and the general public.
    Walker DM; Lefebvre RC; Davis A; Shiu-Yee K; Chen S; Jackson RD; Helme DW; Oga EA; Oser CB; Stotz C; Balvanz P; Asman K; Holloway J; Lewis N; Knudsen HK
    J Subst Use Addict Treat; 2024 Mar; 158():209276. PubMed ID: 38142801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community Attitudes Toward Opioid Use Disorder and Medication for Opioid Use Disorder in a Rural Appalachian County.
    Beachler T; Zeller TA; Heo M; Lanzillotta-Rangeley J; Litwin AH
    J Rural Health; 2021 Jan; 37(1):29-34. PubMed ID: 32738095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Use Disorder Stigma and Support for Harm Reduction in Rural Counties.
    Whipple CR; Kaynak Ö; Kruis NE; Saylor E; Bonnevie E; Kensinger WS
    Subst Use Misuse; 2023; 58(14):1818-1828. PubMed ID: 37622487
    [No Abstract]   [Full Text] [Related]  

  • 6. First Responders' Views of Naloxone: Does Stigma Matter?
    Kruis NE; McLean K; Perry P; Nackley MK
    Subst Use Misuse; 2022; 57(10):1534-1544. PubMed ID: 35791871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm reduction and recovery services support (HRRSS) to mitigate the opioid overdose epidemic in a rural community.
    Heo M; Beachler T; Sivaraj LB; Tsai HL; Chea A; Patel A; Litwin AH; Zeller TA
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):23. PubMed ID: 37076898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substance use and opioid-related stigma among Black communities in the rural South.
    Cody SL; Newman S; Bui C; Sharp-Marbury R; Scott L
    Arch Psychiatr Nurs; 2023 Oct; 46():127-132. PubMed ID: 37813495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 10. Projected Estimates of Opioid Mortality After Community-Level Interventions.
    Linas BP; Savinkina A; Madushani RWMA; Wang J; Eftekhari Yazdi G; Chatterjee A; Walley AY; Morgan JR; Epstein RL; Assoumou SA; Murphy SM; Schackman BR; Chrysanthopoulou SA; White LF; Barocas JA
    JAMA Netw Open; 2021 Feb; 4(2):e2037259. PubMed ID: 33587136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
    Lin Q; Kolak M; Watts B; Anselin L; Pollack H; Schneider J; Taylor B
    Soc Sci Med; 2022 Jul; 305():115034. PubMed ID: 35636049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing communities study.
    Lefebvre RC; Chandler RK; Helme DW; Kerner R; Mann S; Stein MD; Reynolds J; Slater MD; Anakaraonye AR; Beard D; Burrus O; Frkovich J; Hedrick H; Lewis N; Rodgers E
    Drug Alcohol Depend; 2020 Dec; 217():108338. PubMed ID: 33152673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Support for evidence-informed opioid policies and interventions: The role of racial attitudes, political affiliation, and opioid stigma.
    Pyra M; Taylor B; Flanagan E; Hotton A; Johnson O; Lamuda P; Schneider J; Pollack HA
    Prev Med; 2022 May; 158():107034. PubMed ID: 35339585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for community-driven selection of strategies to implement evidence-based practices to reduce opioid overdoses in the HEALing Communities Study: a trial to evaluate a community-engaged intervention in Kentucky, Massachusetts, New York and Ohio.
    Young AM; Brown JL; Hunt T; Sprague Martinez LS; Chandler R; Oga E; Winhusen TJ; Baker T; Battaglia T; Bowers-Sword R; Button A; Fallin-Bennett A; Fanucchi L; Freeman P; Glasgow LM; Gulley J; Kendell C; Lofwall M; Lyons MS; Quinn M; Rapkin BD; Surratt HL; Walsh SL
    BMJ Open; 2022 Sep; 12(9):e059328. PubMed ID: 36123106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HEALing (Helping to End Addiction Long-term
    HEALing Communities Study Consortium
    Drug Alcohol Depend; 2020 Dec; 217():108335. PubMed ID: 33248391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term
    Chandler R; Nunes EV; Tan S; Freeman PR; Walley AY; Lofwall M; Oga E; Glasgow L; Brown JL; Fanucchi L; Beers D; Hunt T; Bowers-Sword R; Roeber C; Baker T; Winhusen TJ
    Drug Alcohol Depend; 2023 Apr; 245():109804. PubMed ID: 36780768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.
    Chatterjee A; Baker T; Rudorf M; Walt G; Stotz C; Martin A; Kinnard EN; McAlearney AS; Bosak J; Medley B; Pinkhover A; Taylor JL; Samet JH; Lunze K
    J Subst Use Addict Treat; 2024 Apr; 159():209272. PubMed ID: 38128649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobile addiction treatment and harm reduction services as tools to address health inequities: a community case study of the Brockton Neighborhood Health Center mobile unit.
    Pinkhover A; Celata K; Baker T; Chatterjee A; Lunze K
    Front Public Health; 2024; 12():1407522. PubMed ID: 38957203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (helping end addiction long-term®) communities study.
    Knudsen HK; Walker DM; Mack N; Kinnard EN; Huerta TR; Glasgow L; Gilbert L; Garner BR; Dasgupta A; Chandler R; Walsh SL; Tin Y; Tan S; Sprunger J; Sprague-Martinez L; Salsberry P; Saucier M; Rudorf M; Rodriguez S; Oser CB; Oga E; Nakayima J; Linas BS; Lefebvre RC; Kosakowski S; Katz RE; Hunt T; Holman A; Holloway J; Goddard-Eckrich D; Fareed N; Christopher M; Aldrich A; Adams JW; Drainoni ML
    Prev Med; 2024 Jun; 185():108034. PubMed ID: 38857770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.